Author

Humberto I. Aguilar

Observed names: H Aguilar, H. Aguilar, Humberto Aguilar

Observed institutions: Regenstrief Institute, Mayo Clinic, Exact Sciences (United States), Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Louisiana State University Health Sciences Center Shreveport

ORCID: 0000-0002-8621-0441

Observed ORCID: 0000-0002-8621-0441

OpenAlex ID: A5113609029

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

2019 · Zobair M Younossi, Vlad Ratziu, et al. · The Lancet · 1,260

PDF

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 · Jordan J. Feld, Kris V. Kowdley, et al. · New England Journal of Medicine · 903

PDF

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

2020 · Stephen A. Harrison, Vincent Wai-Sun Wong, et al. · Journal of Hepatology · 493

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

2017 · Xavier Forns, Samuel S Lee, et al. · The Lancet Infectious Diseases · 343

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

2017 · Paul Y. Kwo, Fred Poordad, et al. · Journal of Hepatology · 302

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

2022 · Sahil Khanna, Maha Assi, et al. · Drugs · 298

PDF

Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening

2024 · Thomas F. Imperiale, Kyle Porter, et al. · New England Journal of Medicine · 244

Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection.

1995 · R Botla, J R Spivey, et al. · Journal of Pharmacology and Experimental Therapeutics · 228

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

2017 · Tarik Asselah, Kris V. Kowdley, et al. · Clinical Gastroenterology and Hepatology · 227

PDF

Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation

1998 · Edward V. Loftus, Humberto I. Aguilar, et al. · Hepatology · 204

PDF

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial

2019 · Robert S. Brown, Maria Buti, et al. · Journal of Hepatology · 154

Risankizumab for Ulcerative Colitis

2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 131

PDF

Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: a potential role for mitochondrial proteases

1998 · Gregory J. Gores, Hideyuki Miyoshi, et al. · Biochimica et Biophysica Acta (BBA) - Bioenergetics · 127

PDF

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine

2015 · Jacob Lalezari, J. Greg Sullivan, et al. · Journal of Hepatology · 119

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

2016 · Edward Gane, Fred Poordad, et al. · Gastroenterology · 103

PDF

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

2021 · Laurent Peyrin-Biroulet, Ailsa Hart, et al. · The Lancet. Gastroenterology & hepatology · 97

PDF

Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial

2022 · William J Sandborn, Julian Panés, et al. · The Lancet. Gastroenterology & hepatology · 66

Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies

2018 · Graham R. Foster, Gregory J. Dore, et al. · Drug and Alcohol Dependence · 40

Development and Pilot Testing of the Inflammatory Bowel Disease Nutrition Care Pathway

2020 · Caroline Hwang, Kelly Issokson, et al. · Clinical Gastroenterology and Hepatology · 23

Enhanced Liver Calpain Protease Activity Is a Risk Factor for Dysfunction of Human Liver Allografts1,2

1997 · Humberto I. Aguilar, Jeffery L. Steers, et al. · Transplantation · 21

Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort

2023 · Arun J. Sanyal, Breda Munoz, et al. · Clinical Gastroenterology and Hepatology · 19

Azathioprine-Induced Lymphoma Manifesting as Fulminant Hepatic Failure

1997 · Humberto I. Aguilar, Lawrence J. Burgart, et al. · Mayo Clinic Proceedings · 18

965: Efficacy and Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Moderately to Severely Active Ulcerative Colitis: 12-week Results From the Phase 2 Lattice-uc Study

2022 · Silvio Danese, Remo Panaccione, et al. · Gastroenterology · 13

Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials

2020 · Fred Poordad, RuiSarmento E. Castro, et al. · Journal of Viral Hepatitis · 13

IDDF2019-ABS-0210 Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1–6 infection and compensated cirrhosis: the EXPEDITION-8 study

2019 · Robert S Brown, Christopher Hezode, et al. · 11

PDF

Works count: 51

Citation count: 6,026

H-index: 21

I10-index: 28